Nicolás Tambucho
CEO
Guska
Guska develops synthetic RNA oncolytic virus therapies that precisely target and eliminate cancer cells while stimulating the immune system. This approach offers a more effective and less harmful alternative to traditional cancer treatments by enhancing the body's ability to fight tumors.
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Pilar Moreno
Co-founder
Gonzalo Moratorio
Co-founder
Product
Problem
Traditional cancer therapies often present significant challenges, including limited efficacy against certain tumor types and substantial side effects due to their impact on healthy tissues. This necessitates the development of treatment modalities that offer improved tumor selectivity and a more favorable safety profile.
Solution
Guska is developing synthetic RNA oncolytic virus therapies engineered to deliver potent and safe immunostimulatory effects. Our platform precisely targets and eliminates cancer cells while preserving adjacent healthy tissue, presenting a more effective and less harmful alternative to conventional treatments. By stimulating a robust endogenous immune response, our therapies aim to enhance the body's capacity to combat tumors, thereby improving patient outcomes.
Target Audience
Our primary target audience includes oncologists, cancer research institutions, and pharmaceutical companies seeking novel therapeutic agents for oncology indications.
Features
- Synthetic RNA oncolytic virus platform designed for targeted cancer cell lysis.
- Engineered to elicit potent and safe immunostimulatory effects within the tumor microenvironment.
- Utilizes precise targeting mechanisms to minimize off-target effects on healthy tissues.
- Aims to activate and amplify the patient's immune system to recognize and attack cancer cells.
- Focuses on improving therapeutic efficacy and reducing the incidence of adverse events compared to standard treatments.